Literature DB >> 10463897

Heartburn treatment in primary care: randomised, double blind study for 8 weeks.

J G Hatlebakk1, A Hyggen, P H Madsen, P O Walle, T Schulz, P Mowinckel, T Bernklev, A Berstad.   

Abstract

OBJECTIVE: To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients.
DESIGN: Randomised, double blind, placebo controlled study.
SETTING: 65 primary care practices in Norway. PARTICIPANTS: 483 untreated patients with complaints of heartburn >/=3 days a week, with at most grade 1 reflux oesophagitis.
INTERVENTIONS: Omeprazole 20 mg once daily, cisapride 20 mg twice daily, or placebo for 8 weeks. MAIN OUTCOME MEASURES: Adequate control of heartburn, defined as </=1 day of the past 7 days with no more than mild heartburn, after 4 weeks of treatment.
RESULTS: In the all patients treated analysis, adequate control of heartburn was achieved in 71% of patients taking omeprazole, 22% taking cisapride, and 18% taking placebo after 4 weeks of treatment (omeprazole v cisapride and placebo, P<0.0001; cisapride v placebo, non-significant). Results were comparable in patients with or without reflux oesophagitis. In patients treated with omeprazole only, symptom control was achieved significantly more often in patients positive for Helicobacter pylori. Antacid use was 2-3 times greater in patients taking cisapride or placebo than in those taking omeprazole. Relief of non-reflux symptoms did not significantly differ between the three groups. Significantly more patients taking cisapride reported adverse events than those taking omeprazole or placebo.
CONCLUSIONS: Omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463897      PMCID: PMC28208          DOI: 10.1136/bmj.319.7209.550

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  18 in total

1.  Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease.

Authors:  G J Maddern; G G Jamieson; J C Myers; P J Collins
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

2.  The endoscopic assessment of esophagitis: a progress report on observer agreement.

Authors:  D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

3.  Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996.

Authors:  R C Heading; F Baldi; R H Holloway; J Janssens; R Jian; R W McCallum; J E Richter; C Scarpignato; S J Sontag; M Wienbeck
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-01       Impact factor: 2.566

4.  Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

Authors:  J P Galmiche; P Barthelemy; B Hamelin
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

5.  Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.

Authors:  D O Castell; C Sigmund; D Patterson; R Lambert; D Hasner; C Clyde; J B Zeldis
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

6.  Mechanisms of gastroesophageal reflux in ambulant healthy human subjects.

Authors:  M N Schoeman; M D Tippett; L M Akkermans; J Dent; R H Holloway
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

7.  The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; F Johnsson; M Vilien; L Carling; S Wetterhus; T Thøgersen
Journal:  Scand J Gastroenterol       Date:  1997-11       Impact factor: 2.423

8.  Ineffective esophageal motility (IEM): the primary finding in patients with nonspecific esophageal motility disorder.

Authors:  L P Leite; B T Johnston; J Barrett; J A Castell; D O Castell
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

9.  Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.

Authors:  J G Hatlebakk; A Berstad; L Carling; L E Svedberg; P Unge; P Ekström; L Halvorsen; A Stallemo; N Hovdenak; R Trondstad
Journal:  Scand J Gastroenterol       Date:  1993-03       Impact factor: 2.423

10.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

View more
  19 in total

Review 1.  Management of gastro-oesophageal reflux disease in general practice.

Authors:  J Dent; R Jones; P Kahrilas; N J Talley
Journal:  BMJ       Date:  2001-02-10

2.  Heartburn treatment in primary care. Prescribing omeprazole would conflict with desire to control prescribing costs.

Authors:  A Williams
Journal:  BMJ       Date:  2000-05-20

3.  How well is the clinical importance of study results reported? An assessment of randomized controlled trials.

Authors:  K B Chan; M Man-Son-Hing; F J Molnar; A Laupacis
Journal:  CMAJ       Date:  2001-10-30       Impact factor: 8.262

Review 4.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

5.  Helicobacter pylori infection and long term proton pump inhibitor therapy.

Authors:  K E L McColl
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  Clinical outcomes after laparoscopic antireflux surgery in patients with and without preoperative endoscopic esophagitis.

Authors:  Ketan M Desai; Margaret M Frisella; Nathaniel J Soper
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 7.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 8.  Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?

Authors:  Andrew J Gawron; John E Pandolfino
Journal:  Curr Gastroenterol Rep       Date:  2013-04

9.  An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

10.  Obesity as a risk factor for GERD in Japan.

Authors:  Masahiro Sakaguchi; Hiroshi Oka; Takashi Hashimoto; Yutaka Asakuma; Miyuki Takao; Goki Gon; Makoto Yamamoto; Yoshihisa Tsuji; Norihiko Yamamoto; Mamoru Shimada; Kyowon Lee; Kiyoshi Ashida
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.